Posted by iCELL News, on 29th March 2012, in Stem Cell Research.
AxoGen, Inc. (OTCBB: AXGN), a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announces the release of an updated corporate fact sheet.




AxoGen Logo
“2011 resulted in year on year revenue growth of 61%. We have updated the fact sheet to reflect the 2011 results and the continued growth of our business,” commented Karen Zaderej, Chief Executive Officer of AxoGen, Inc.

Alachua, FL (PRWEB) March 29, 2012
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, today announced that it has released an updated corporate fact sheet.
“2011 resulted in year on year revenue growth of 61%. We have updated the fact sheet to reflect the 2011 results and the continued growth of our business,” commented Karen Zaderej, Chief Executive Officer of AxoGen, Inc. “We are committed to providing current, accessible information about AxoGen and our peripheral nerve repair and regeneration solutions to help the market understand our technologies, our results and our market.”
The new AxoGen Corporate Fact Sheet is available under the “Investor” tab on the Company’s website, http://www.axogeninc.com.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance® Nerve Graft, which AxoGen believes is the only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed).
AxoGen’s portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html .
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.